Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Cancer Res. 2018 Oct 24;17(2):583–593. doi: 10.1158/1541-7786.MCR-18-0777

Figure 1. Identification of oncogenic mutations arising spontaneously in Cdkn2a (Ink4a/Arf) and Pten null (IP) tumors.

Figure 1.

An illustration of the IP mouse model (A) where topical 4OHT treatment induces Cre activation within melanocytes and subsequent Ink4a/Arf and Pten deletion (B: PCR analysis of ear and tumor DNA). Gross and histological representations of melanomas arising in IP mice (C). Results of whole exome sequencing performed on melanoma and matched normal tissue samples from IP mice (D). KRAS A146T and Ptpn11 S506P mutation is confirmed by Sanger sequencing in melanoma, but not in matched normal DNA of PA543 and PA624 mice, respectively (E).